Schizophrenia

NEW ORLEANS — Most investigators concluded that telemedicine is satisfactory for patients with schizophrenia being treated with long-acting injectable psychotics, according to survey results presented at the American Psychiatric Association meeting.

The FDA has granted approval to Intra-Cellular Therapies Inc. for 10.5 mg and 21 mg dosages of lumateperone to treat schizophrenia and bipolar depression, according to a company release.

The FDA has issued a Complete Response Letter for the New Drug Application for risperidone extended-release injectable for subcutaneous use, a schizophrenia treatment, Teva Pharmaceuticals and MedinCell announced in a statement.

OxfordVR has announced a successful new virtual reality therapy for patients with mental illnesses such as schizophrenia and mood disorders with psychotic symptoms.

BioXcel Therapeutics has announced the FDA approval of Igalmi, a sublingual film for acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.

People with schizophrenia were less likely to have received a COVID-19 booster, while gaps in acquisition were greatest for the first vaccination, according to a retrospective cohort study published in JAMA Psychiatry.

Individuals with serious mental illnesses such as bipolar disorder and schizophrenia may experience greater 10- and 30-year CV risk compared with those without a serious mental illness, researchers reported.

Alkermes announced positive topline results from its phase 3b study of Lybalvi in young adults with schizophrenia, schizophreniform disorder or bipolar I disorder who were early in their illness.

Patients with schizophrenia who were treated with 3-monthly paliperidone in a clinical setting required rehospitalization less often, according to a 5-year U.K. mirror image study published in the Journal of Psychiatric Research.

Healio’s most-viewed psychiatry stories in January highlight the global burden of mental disorders on health, a survey that provides insights into Americans’ support of psychedelics and a regulatory development for Rexulti.